Medical Oncology melanoma research

In 2014, our focus in melanoma research moved from advanced disease to treating earlier stage disease with the hope of finding effective systemic adjuvant treatments.

Earlier research involving many Alfred patients established targeted therapy as the new standard of care for advanced melanoma in which a B-Raf mutation is detected.

In 2014 we were involved in two large international studies looking at the role of targeted therapies as potential adjuvant treatments for stage III melanoma. As the highest recruiter in Victoria to these studies, The Alfred has played a major role in rapidly moving this area forward.

In other translational research, Dr Haydon is a co-investigator on a multimillion VCA award entitled ‘The Melbourne Melanoma Project: Translating immunology and molecular biospecimen profiles into the management of melanoma patients’. This project is led by Professor Grant McArthur of Peter MacCallum Cancer Centre and other Alfred Research Alliance participants are the heads of the Victorian Melanoma Service (Professor John Kelly) and Anatomical Pathology (Professor Catriona McLean).

Melanoma research is also conducted by the Victorian Melanoma Service, in partnership with the Medical Oncology and the Melbourne Melanoma Project.

Find out more about Victorian Melanoma Service research.

Our partners

Publications

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

Pilgrim CHC, Maciejewska A, Ayres N, Ellis S, Goodwin M, Zalcberg JR, Haydon A

(2022), ANZ J Surg, 92(10), 2565-70

DOI: 10.1111/ans.17999

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years

Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q

(2022), Eur J Cancer, 163, 1-15

DOI: 10.1016/j.ejca.2021.12.007

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators

(2022), Lancet, 399(10336), 1718-29

DOI: 10.1016/S0140-6736(22)00562-1

View all publications for Medical Oncology melanoma research